SCM
MRSN

Scopia Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Scopia Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,145
Closed -$2.85M – 38
2017
Q2 		$2.85M Buy
+8,145
New +$2.82M 0.06% 32

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Scopia Capital Management's MRSN Position: Q3 2017 in Review

Scopia Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2017, closing a stake of 8,145 shares — an estimated $2.85M sold.

Scopia Capital Management first reported a position in MRSN in Q2 2017 and held it in 1 quarter. The position peaked at $2.85M in Q2 2017. 42 funds tracked by Wall St. Rank hold MRSN as of Q3 2017.

  • Scopia Capital Management reported no remaining Mersana Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Scopia Capital Management sold 8,145 Mersana Therapeutics shares in Q3 2017, an estimated $2.85M.
  • Scopia Capital Management first reported a position in Mersana Therapeutics in Q2 2017 and held it in 1 quarter.
  • Scopia Capital Management's Mersana Therapeutics position peaked at $2.85M in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2017.

Based on Scopia Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.